Å. Helland

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Aslaug Helland, A Helland, Å. Helland, Å Helland, A. Helland, Âslaug Helland, Åslaug Helland, Ȧslaug Helland
Publication record
272 papers · 9,833 citations · H-index 49

PAPERS

Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
20254 citationsauthor #7
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
20250 citationsauthor #21
Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway
20250 citationsauthor #7
Abstract 2413: Mutated TP53 prevalence in EGFR-mutated advanced non-small cell lung cancer patients with brain metastases
20240 citationsauthor #4
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends.
20244 citationsauthor #7
Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial
20240 citationsauthor #9
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
20247 citationsauthor #9
Distribution and characteristics of malignant tumours by lung lobe
20246 citationsauthor #4
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
20243 citationsauthor #18
A two‐phase epigenome‐wide four‐way gene–smoking interaction study of overall survival for early‐stage non‐small cell lung cancer
20240 citationsauthor #14
Sex differences in burden of adverse events in patients receiving immunotherapy.
20238 citationsauthor #19
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
20233 citationsauthor #3
IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.
20230 citationsauthor #1
2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
202331 citationsauthor #8
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
202319 citationsauthor #22
Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
202310 citationsauthor #7
Erratum: “MRI pulse sequence integration for deep‐learning‐based brain metastases segmentation”
20230 citationsauthor #10
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry
202313 citationsauthor #50
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
202232 citationsauthor #2
Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy
20229 citationsauthor #5
Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
202221 citationsauthor #4
1315O Key learnings from building: A precision cancer medicine implementation initiative for Norway
20220 citationsauthor #20
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
20226 citationsauthor #9
EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.
20225 citationsauthor #1
Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.
20223 citationsauthor #3
Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
20223 citationsauthor #7
1145P Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: The ComIT-1 trial
20220 citationsauthor #7
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
202228 citationsauthor #1
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
20220 citationsauthor #1
A national precision cancer medicine implementation initiative for Norway
202216 citationsauthor #123
Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer
20220 citationsauthor #7
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
20226 citationsauthor #9
Common variants in breast cancer risk loci predispose to distinct tumor subtypes
20222 citationsauthor #50
A trans‐omics assessment of gene–gene interaction in early‐stage NSCLC
20226 citationsauthor #13
Concordance between clinical and pathology TNM-staging in lung cancer.
202212 citationsauthor #5
Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
202211 citationsauthor #12
Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
20226 citationsauthor #3
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
20221 citationsauthor #8
P59.18 Evaluation of ROS1 Expression in a Large Cohort of Early Stage Lung Cancer
20210 citationsauthor #5
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
202118 citationsauthor #3
Author response for "Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor"
20210 citationsauthor #8
Age-related treatment patterns for stage I NSCLC in three European countries.
202115 citationsauthor #5
Immune landscape evaluation of NSCLC clinical samples
20211 citationsauthor #23
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
202187 citationsauthor #23
P17.02 Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study
20211 citationsauthor #15
Mass spectrometry-based proteomic analysis of NSCLC tumor and biopsy samples
20211 citationsauthor #23
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
202116 citationsauthor #8
The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
202161 citationsauthor #7
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
20217 citationsauthor #9
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
202118 citationsauthor #7
P59.15 Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)?
20210 citationsauthor #3
Epigenome‐wide three‐way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early‐stage NSCLC
20219 citationsauthor #13
OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC
20215 citationsauthor #2
P28.03 Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience
20210 citationsauthor #7
P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)
20210 citationsauthor #9
Handling missing MRI sequences in deep learning segmentation of brain metastases: a multicenter study
202141 citationsauthor #9
STK11 pathway in vitro validation
20211 citationsauthor #23
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
20215 citationsauthor #3
63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID)
202111 citationsauthor #6
Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
202112 citationsauthor #8
1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment
20215 citationsauthor #13
COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
202148 citationsauthor #7
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
202122 citationsauthor #10
Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
2021109 citationsauthor #4
Bioinformatics analysis of NSCLC multi-omics data
20212 citationsauthor #23
Antibody combinations for optimized staining of macrophages in human lung tumours
202019 citationsauthor #8
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
20209 citationsauthor #7
Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
20208 citationsauthor #9
Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
202017 citationsauthor #3
Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
202033 citationsauthor #26
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
20207 citationsauthor #9
Epigenome-wide gene–age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
202013 citationsauthor #23
Radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC): A prospective, observational study.
20200 citationsauthor #6
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
20205 citationsauthor #2
OC-0095: Timing of immunotherapy and SRS – Does it affects the outcome of patients with brain metastases?
20200 citationsauthor #5
Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
20207 citationsauthor #10
Epigenetic–smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early‐stage NSCLC patients
202013 citationsauthor #24
1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)
20200 citationsauthor #7
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
20206 citationsauthor #9
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
202055 citationsauthor #2
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer – predictors of response and impact of previous radiotherapy
202010 citationsauthor #8
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk
20205 citationsauthor #57
SP-0758: The immune microenvironment in lung cancer - impact on effect of combined radiotherapy and immunotherapy?
20200 citationsauthor #1
1403P EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study
20200 citationsauthor #1
A 10‐year prediagnostic follow‐up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
201915 citationsauthor #5
Protein kinase C isozymes; predictors of progression free survival in NSCLC patients
20190 citationsauthor #9
The cellular proteome of pancreatic ductal adenocarcinoma
20190 citationsauthor #8
Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries.
20192 citationsauthor #5
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
201911 citationsauthor #7
P1.01-72 A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
20193 citationsauthor #3
A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
20193 citationsauthor #5
MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC
20193 citationsauthor #3
Handling Missing MRI Input Data in Deep Learning Segmentation of Brain Metastases: A Multi-Center Study
20192 citationsauthor #9
SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic–smoking interaction analysis
201922 citationsauthor #23
EP1.18-12 The Neutrophil and Platelet to Lymphocyte Ratios and Glasgow Prognostic Score as a Predictor for Relapse After Stereotactic Radiation for Lung Cancer
20191 citationsauthor #5
PO-1000 Vascular responses in normal brain tissue after combined immunotherapy and SRS to brain metastases
20191 citationsauthor #11
The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
201960 citationsauthor #8
MRI Pulse Sequence Integration for Deep-Learning Based Brain Metastasis Segmentation
201911 citationsauthor #10
Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status: Putative targets
20190 citationsauthor #9
PathTracer: High-sensitivity detection of differential pathway activity in tumours
20193 citationsauthor #6

TIMELINE

1992 103 citations

1993 144 citations

1997 83 citations

1998 188 citations

1999 0 citations

2000 20 citations

2001 11 citations

2003 14 citations

2004 141 citations

2005 178 citations

2006 27 citations

2007 54 citations

2009 282 citations

2010 226 citations

2011 1,272 citations

2012 122 citations

2013 553 citations

2014 954 citations

2015 591 citations

2016 2,108 citations

2017 254 citations

2018 1,076 citations

2019 476 citations

2020 207 citations

2021 495 citations

2022 167 citations

2023 84 citations

2024 20 citations

2025 4 citations

Å. Helland

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT